Filing Details

Accession Number:
0001193125-23-201784
Form Type:
13D Filing
Publication Date:
2023-08-01 20:00:00
Filed By:
Carlyle Group Inc.
Company:
Vera Therapeutics Inc.
Filing Date:
2023-08-02
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
The Carlyle Group Inc 0 1,872,764 0 1,872,764 1,872,764 4.2%
Carlyle Holdings I GP Inc 0 1,872,764 0 1,872,764 1,872,764 4.2%
Carlyle Holdings I GP Sub 0 1,872,764 0 1,872,764 1,872,764 4.2%
Carlyle Holdings I 0 1,872,764 0 1,872,764 1,872,764 4.2%
CG Subsidiary Holdings 0 1,872,764 0 1,872,764 1,872,764 4.2%
TC Group 0 1,872,764 0 1,872,764 1,872,764 4.2%
Carlyle Investment Management 0 1,872,764 0 1,872,764 1,872,764 4.2%
Carlyle Genesis UK 0 1,872,764 0 1,872,764 1,872,764 4.2%
Abingworth LLP 0 1,872,764 0 1,872,764 1,872,764 4.2%
Abingworth Bioventures 0 1,872,764 0 1,872,764 1,872,764 4.2%
Filing

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

 

 

Vera Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

92337R101

(CUSIP Number)

Jeffrey Ferguson

The Carlyle Group

1001 Pennsylvania Avenue, NW

Suite 220 South

Washington, D.C. 20004

(202) 729-5626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 18, 2023

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 92337R101    13D    Page 1 of 14 pages

 

  1    

  Names of Reporting Persons

 

  The Carlyle Group Inc.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  CO

 


CUSIP No. 92337R101    13D    Page 2 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Carlyle Holdings I GP Inc.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  CO

 


CUSIP No. 92337R101    13D    Page 3 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Carlyle Holdings I GP Sub L.L.C.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  OO (Limited Liability Company)

 


CUSIP No. 92337R101    13D    Page 4 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Carlyle Holdings I L.P.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  PN

 


CUSIP No. 92337R101    13D    Page 5 of 14 pages

 

  1    

  Names of Reporting Persons

 

  CG Subsidiary Holdings L.L.C.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  OO (Limited Liability Company)

 


CUSIP No. 92337R101    13D    Page 6 of 14 pages

 

  1    

  Names of Reporting Persons

 

  TC Group, L.L.C.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  OO (Limited Liability Company)

 


CUSIP No. 92337R101    13D    Page 7 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Carlyle Investment Management L.L.C.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  OO (Limited Liability Company)

 


CUSIP No. 92337R101    13D    Page 8 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Carlyle Genesis UK LLC

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  OO (Limited Liability Company)

 


CUSIP No. 92337R101    13D    Page 9 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Abingworth LLP

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  England and Wales

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  PN

 


CUSIP No. 92337R101    13D    Page 10 of 14 pages

 

  1    

  Names of Reporting Persons

 

  Abingworth Bioventures 8 LP

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Source of Funds (See Instructions)

 

  OO

  5  

  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  ☐

  6  

  Citizenship or Place of Organization

 

  England and Wales

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7     

  Sole Voting Power

 

  0

     8   

  Shared Voting Power

 

  1,872,764

     9   

  Sole Dispositive Power

 

  0

   10   

  Shared Dispositive Power

 

  1,872,764

11    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,872,764

12  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

  ☐

13  

  Percent of Class Represented by Amount in Row (11)

 

  4.2%

14  

  Type of Reporting Person

 

  PN

 


CUSIP No. 92337R101    13D    Page 11 of 14 pages

 

Explanatory Note

This Amendment No. 5 to Schedule 13D (Amendment No. 5) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the SEC) on May 24, 2021 (as amended to date, the Schedule 13D), relating to the shares of Class A common stock, par value $0.001 per share (the Class A Common Stock), of Vera Therapeutics, Inc., a Delaware corporation (the Issuer). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.

 

Item 5.

Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 44,261,109 shares of Class A Common Stock outstanding as of May 5, 2023, as disclosed in the Issuers quarterly report on Form 10-Q filed on May 11, 2023.

 

Reporting Person

   Amount
beneficially
owned
     Percent
of class
    Sole
power to
vote or to

direct the
vote
     Shared
power to
vote or to
direct the
vote
     Sole power
to dispose
or to direct
the
disposition
     Shared
power to
dispose or to
direct the
disposition
 

The Carlyle Group Inc.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Carlyle Holdings I GP Inc.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Carlyle Holdings I GP Sub L.L.C.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Carlyle Holdings I L.P.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

CG Subsidiary Holdings L.L.C.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

TC Group, L.L.C.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Carlyle Investment Management L.L.C.

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Carlyle Genesis UK LLC

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Abingworth LLP

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Abingworth Bioventures 8 LP

     1,872,764        4.2     0        1,872,764        0        1,872,764  

Abingworth Bioventures 8 LP is the record holder of the shares of Class A Common Stock reported herein.


CUSIP No. 92337R101    13D    Page 12 of 14 pages

 

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures 8 LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures 8 LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures 8 LP, but each disclaims beneficial ownership of such securities.

(c) In addition to the trades reported on Amendment No. 4, from July 11, 2023 through July 31, 2023, Abingworth Bioventures 8 LP disposed of 544,073 shares of Class A Common Stock in a series of open-market transactions. Details by date, listing the number of shares of Class A Common Stock disposed of and the weighted average price per share, are provided below. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for each transaction.

 

Date

  

Shares Disposed Of

  

Price Range

  

Weighted Average Price Per
Share

July 11, 2023

   1,147    $16.97 to $16.97    $16.97

July 12, 2023

   66,477    $16.97 to $17.555    $17.1147

July 13, 2023

   200    $16.97 to $16.99    $16.98

July 14, 2023

   403    $16.97 to $17.00    $16.9813

July 17, 2023

   73,416    $16.97 to $17.385    $17.1032

July 18, 2023

   113,740    $17.00 to $17.88    $17.2871

July 19, 2023

   67,985    $16.97 to $17.585    $17.1653

July 20, 2023

   18,517    $16.97 to $17.135    $16.9948

July 21, 2023

   16,372    $16.97 to $17.27    $17.0397

July 24, 2023

   3,601    $16.97 to $17.08    $17.013

July 27, 2023

   6,548    $16.97 to $17.055    $16.9971

July 28, 2023

   56,586    $16.97 to $17.305    $17.0664

July 31, 2023

   60,528    $17.16 to $18.15    $17.7877

July 31, 2023

   58,553    $18.17 to 18.835    $18.5268

(d) None.

(e) As of July 18, 2023, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding shares of Class A Common Stock.


CUSIP No. 92337R101    13D    Page 13 of 14 pages

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 2, 2023

 

The Carlyle Group Inc.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Chief Financial Officer
Carlyle Holdings I GP Inc.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Managing Director and Chief Financial Officer
Carlyle Holdings I GP Sub L.L.C.
By: Carlyle Holdings I GP Inc., its sole member
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Managing Director and Chief Financial Officer
Carlyle Holdings I L.P.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Managing Director
CG Subsidiary Holdings L.L.C.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Managing Director
TC Group, L.L.C.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Managing Director

CUSIP No. 92337R101    13D    Page 14 of 14 pages

 

Carlyle Investment Management L.L.C.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Chief Financial Officer
Carlyle Genesis UK LLC
By: Carlyle Investment Management L.L.C., its sole member
By:   /s/ Anne Frederick, attorney-in-fact
Name:   Curtis L. Buser
Title:   Chief Financial Officer
Abingworth LLP
By:   /s/ John Heard
Name:   John Heard
Title:   Authorized Signatory
Abingworth Bioventures 8 LP
By:   /s/ John Heard
Name:   John Heard
Title:   Authorized Signatory

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)